001     1010192
005     20230929112543.0
024 7 _ |a 10.3988/jcn.2022.0302
|2 doi
024 7 _ |a 1738-6586
|2 ISSN
024 7 _ |a 2005-5013
|2 ISSN
024 7 _ |a 10.34734/FZJ-2023-03003
|2 datacite_doi
024 7 _ |a 37417432
|2 pmid
024 7 _ |a WOS:001026974600005
|2 WOS
037 _ _ |a FZJ-2023-03003
082 _ _ |a 610
100 1 _ |a Burghaus, Lothar
|0 P:(DE-HGF)0
|b 0
|e Corresponding author
245 _ _ |a Prehospital Levetiracetam Use in Adults With Status Epilepticus: Results of a Multicenter Registry
260 _ _ |a Seoul
|c 2023
|b [Verlag nicht ermittelbar]
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1692187729_26395
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Background and PurposeStatus epilepticus (SE) is a neurological emergency due to prolonged seizure activity or multiple seizures without full recovery in between them. Prehospital SE management is crucial since its duration is correlated with higher morbidity and mortality rates. We examined the impact of different therapeutic strategies in the prehospital setting with a focus on levetiracetam.MethodsWe initiated the Project for SE in Cologne, a scientific association of all neurological departments of Cologne, the fourth-largest city in Germany with around 1,000,000 inhabitants. All patients with an SE diagnosis were evaluated over 2 years (from March 2019 to February 2021) to determine whether prehospital levetiracetam use had a significant effect on SE parameters.ResultsWe identified 145 patients who received initial drug therapy in the prehospital setting by professional medical staff. Various benzodiazepine (BZD) derivatives were used as first-line treatments, which were mostly used in line with the recommended guidelines. Levetiracetam was regularly used (n=42) and mostly in combination with BZDs, but no significant additional effect was observed for intravenous levetiracetam. However, it appeared that the administered doses tended to be low.ConclusionsLevetiracetam can be applied to adults with SE in prehospital settings with little effort. Nevertheless, the prehospital treatment regimen described here for the first time did not significantly improve the preclinical cessation rate of SE. Future therapy concepts should be based on this, and the effects of higher doses should in particular be reexamined. Keywords:neurological emergency; prehospital setting; anticonvulsant therapy; benzodiazepines; levetiracetam
536 _ _ |a 5251 - Multilevel Brain Organization and Variability (POF4-525)
|0 G:(DE-HGF)POF4-5251
|c POF4-525
|f POF IV
|x 0
536 _ _ |a DFG project 491111487 - Open-Access-Publikationskosten / 2022 - 2024 / Forschungszentrum Jülich (OAPKFZJ) (491111487)
|0 G:(GEPRIS)491111487
|c 491111487
|x 1
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Madlener, Marie
|0 0000-0002-6299-8238
|b 1
700 1 _ |a Kohle, Felix
|0 0000-0002-4429-0367
|b 2
700 1 _ |a Bruno, Emanuel F.
|b 3
700 1 _ |a Limmroth, Volker
|0 0000-0003-1607-2116
|b 4
700 1 _ |a Fink, Gereon Rudolf
|0 P:(DE-Juel1)131720
|b 5
|u fzj
700 1 _ |a Malter, Michael P.
|0 0000-0003-2535-4553
|b 6
773 _ _ |a 10.3988/jcn.2022.0302
|g Vol. 19, no. 4, p. 365 -
|0 PERI:(DE-600)2500489-X
|n 4
|p 365 -
|t Journal of clinical neurology
|v 19
|y 2023
|x 1738-6586
856 4 _ |u https://juser.fz-juelich.de/record/1010192/files/PDF.pdf
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:1010192
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 5
|6 P:(DE-Juel1)131720
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5251
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-03-30
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-05-12T12:46:13Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-05-12T12:46:13Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-03-30
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-24
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Double anonymous peer review
|d 2022-05-12T12:46:13Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-24
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J CLIN NEUROL : 2022
|d 2023-08-24
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-24
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21